Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NM Drug List Coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2026 Pharmacy Drug List and Coverage Guide — Drug List and Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Blue Cross and Blue Shield of New Mexico's 2026 drug list and companion guidance describing covered outpatient pharmacy drugs, tiering, specialty drug handling, prior authorization, step therapy, quantity limits, and member/provider processes.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Pharmacy Drug List and Coverage Guide — Drug List and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization (PA) when a drug line indicates PA and provide supporting documentation to justify authorization and requested quantity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MyPrime.comwebsites for current drug list
    Accredospecialty pharmacy partner
    multipleentries with QL/PA/SP
    ~120+distinct listed products (sample segments)
    30/90day supply options

    Coverage Criteria and Formulary Rules

    General coverage conditions

    Covered when ALL of the following are met

    On-list and benefit-eligible: Drug appears on the BCBSNM Drug List and is included in the member's benefit plan coverage

    Drugs not shown are not covered

    Prior Authorization if required: If the drug is marked 'PA' on the drug list, a prior authorization must be submitted and approved before coverage

    For medications listed, PA is generally noted next to the medication in the Special Requirements column; some plans may require PA on additional medications

    Step Therapy if required: If the drug is marked 'ST', required first-line therapy must be tried or an approved exception obtained

    Step therapy (ST) is noted next to medications when applicable; prescribers may request step therapy exceptions

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2026 Pharmacy Drug List and Coverage Guide — Drug List and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization (PA) when a drug line indicates PA and provide supporting documentation to justify authorization and requested quantity.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesFormulary Listings and Code TablesProvider Requirements, Prior Authorization & Step TherapyInitial Therapy and Authorization RulesStep Therapy Rules and Affected AgentsQuantity Limits and ExamplesSite of Care and Specialty PharmacyTerminology and AbbreviationsBackground and Scope
    Dispensing/Quantity Limits: Prescriptions must not exceed plan dispensing limits or quantity limits noted (QL); member may be responsible for costs beyond the limit

    Dispensing limits (QL/DL) and supply (30- or 90-day) conventions are described in the plan materials

    Formulary coverage stance

    Coverage entries shown with tiering and utilization management annotations

    Formulary entries: Drugs are listed with a Drug Tier (e.g., P or NP) and, where specified, utilization controls such as PA, QL, SP, or AC. Specific clinical indication criteria are not provided in this section of the document.

    Examples in the list include antiretrovirals and antifungals annotated with PA/QL/SP where applicable

    Formulary coverage and management per drug entry

    Coverage indicated per drug entry with formulary tier and management codes

    Per-product management: Each listed drug/vaccine entry includes a Drug Tier and Requirements/Limits field (e.g., QL, PA, SP, AC). Coverage and any utilization management requirement apply as shown for that product line.

    Clinical medical necessity rules are not present in these listing fragments; see full PA criteria where applicable

    General coverage conditions

    Coverage subject to product-level administrative controls

    Administrative controls apply: Coverage of each listed product requires adherence to the Requirements/Limits field (for example: prior authorization when 'PA' is listed, respecting quantity limits 'QL', and dispensing via specialty pharmacy when 'SP' is listed).

    This segment lists antineoplastics and specialty agents with PA/QL/SP annotations; clinical approval criteria are located elsewhere

    Operational coverage conditions

    Coverage is contingent on meeting the operational requirements listed per drug presentation

    Operational requirements: Drug coverage requires meeting all listed operational conditions adjacent to the drug (e.g., submit and obtain prior authorization where 'PA' is listed; adhere to specified quantity limits 'QL'; route dispensing through specialty pharmacy when 'SP' is listed).

    Operational controls are provided inline with product entries (examples: EOHILIA PA+QL; prednisolone solutions QL/PA entries)

    Formulary coverage and management by product

    Coverage and utilization management decisions for individual drugs as listed below:

    Corticosteroids and endocrine agents: Multiple corticosteroid, androgen, and endocrine formulations are listed with tier assignments and specific Requirements/Limits (examples include budesonide oral suspension EOHILIA with PA and QL; prednisolone solutions with QL; testosterone injections with QL).

    See each product line for the exact Requirements/Limits values

    Androgens/Testosterone products

    Testosterone formulations have variable requirements:

    Testosterone formulations: Transdermal gels, injections, and auto-injectors are listed with variable Requirements/Limits. Examples include testosterone cypionate IM 100 mg/ml (QL 1 vial/28 days) and auto-injector presentations (XYOSTED, XYOSTED-like products) noted with PA and QL (e.g., 4 pens/28 days for some auto-injectors).QL (1 vial/28 days) for testosterone cypionate (example)

    Providers should submit PA where indicated and follow per-product QL

    Estrogens and related combination products

    Various estrogen therapies are included with tiering and quantity limits:

    threshold":"QL (30 patches/30 days) for common patch examples","note":"Refer to each product line for exact QL/PA entries","children":[]}

    Contraceptives

    Multiple contraceptive products with AC/QL/PA designations:

    Contraceptives: Contraceptive products are annotated with AC (ACA preventive/coverage), QL (commonly 28 tablets/21 days) and occasionally PA. Emergency contraception (ELLA) is shown with AC and QL (2 tablets/365 days).QL (28 tablets/21 days) (common)

    AC indicates ACA preventive coverage where applicable and coverage may vary by benefit plan

    Per-product coverage statements

    Coverage and utilization controls as listed per product

    Per-product listing: Each drug entry shows plan Drug Tier and any Requirements/Limits such as PA (prior authorization), QL (quantity limit), AC (Affordable Care Act preventive), and SP (specialty pharmacy). Coverage and utilization management are applied as shown for each product line.See per-product Requirements/Limits

    This block reflects the per-line controls shown across the formulary; clinical indication criteria are not included in these chunks.

    Formulary requirement indicators

    Coverage and requirement indicators present in this fragment:

    PA required: Multiple listed drugs include 'PA' in Requirements/Limits indicating prior authorization is required for coverage (examples across endocrine and specialty agents such as ACTHAR, CRENESSITY, PALYNZIQ).

    See individual product lines for exact PA requirements

    Quantity limits (QL): Many products include specific QL values (insulin products commonly QL 100 mls/30 days; other QLs vary by drug).100 mls/30 days (common for insulins)

    Per-product limits are listed next to each drug name

    Specialty designation (SP): High-cost or complex agents are designated 'SP' (specialty) and may require specialty pharmacy dispensing and management.

    Examples include ACTHAR, GALAFOLD, IMCIVREE

    Step therapy (ST): Selected products indicate 'ST' (step therapy) which may require trials of preferred therapies first (example: KERENDIA).

    Consult full policy for step therapy algorithms

    Administrative coverage criteria (partial list)

    Coverage and administrative requirements for listed products

    Administrative requirements apply: Many specialty and orphan drugs listed require prior authorization (PA) and routing through a specialty pharmacy (SP); some also have defined quantity limits (QL). Providers must request PA and adhere to QL/SP requirements where specified.

    Examples include SOMAVERT, VOXZOGO, SKYTROFA listed with PA and SP

    Cardiovascular drug listings

    Standard cardiovascular agents listed

    Formulary listing: Various cardiovascular drug classes (cardiotonics, antianginal agents, beta blockers, calcium channel blockers, antihypertensives) are listed with Drug Tier designations and Requirements/Limits where specified.

    No specific clinical PA criteria are provided in this segment; see per-product entries for PA/QL values

    Formulary coverage entries

    Coverage is indicated per listed product with associated utilization controls where specified.

    Formulary coverage entries: Each listed product includes a Drug Tier and, when present, Requirements/Limits such as PA (prior authorization), QL (quantity limit), and SP (specialty pharmacy). Coverage is subject to meeting those controls as shown.

    No patient-level clinical criteria are present in this fragment; see full policy for medical necessity criteria

    Formulary coverage conditions

    Coverage is provided according to formulary tier, with additional utilization controls as specified below

    Formulary coverage with utilization controls: Drugs listed include a Drug Tier assignment and may include Requirements/Limits such as PA (prior authorization), QL (quantity limits), SP (specialty pharmacy). Where PA is listed, approval is required prior to dispensing for coverage.

    This excerpt does not include detailed clinical eligibility criteria; see product-specific policies for clinical PA rules

    Drugs are covered only if they appear on the BCBSNM Drug List and are included in the member’s benefit plan. Drugs not shown on the drug list are not covered; repackaged products and medications that have not received FDA approval are also not covered. Some products that have over‑the‑counter equivalents or are used for cosmetic indications may be excluded by the member’s benefit. Refer to the member’s specific plan documents or call the number on the member ID card for coverage determinations.

    This document does not present a separate list of explicitly excluded products in the section shown. Instead, individual drug lines identify a Drug Tier and any applicable utilization controls such as PA (prior authorization), QL (quantity limit), SP (specialty pharmacy), or AC. Coverage decisions follow the per‑product annotations shown on the formulary lines.

    Coverage is determined by the drug list and the member’s benefit plan. Where a product line shows utilization controls (for example, PA, QL, or SP), the provider must follow those administrative requirements for coverage to be approved. For site‑of‑care questions (for example, drugs administered by a health care professional), refer to plan materials because some products may be covered under the medical benefit rather than the pharmacy benefit.

    Formulary Listings and Code Tables

    Formulary drug entries and strengthsmixed
    amoxicillin (trihydrate) chew tab 125 mg, 250 mgListed formulary product and strengths
    amoxicillin (trihydrate) cap 250 mg, 500 mgListed formulary product and strengths
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlListed formulary product and strengths
    amoxicillin (trihydrate) tab 500 mg, 875 mgListed formulary product and strengths
    amoxicillin & k clavulanate for susp 200-28.5 mg/5ml; 250-62.5 mg/5ml; 400-57 mg/5ml; 600-42.9 mg/5mlListed formulations including Augmentin ES-600
    amoxicillin & k clavulanate tab 250-125 mg; 500-125 mg; 875-125 mg; ER 1000-62.5 mgTablet strengths listed
    ampicillin cap 500 mgListed product
    cefadroxil tab 1 gm; cap 500 mgCephalosporin entries
    cefdinir cap 300 mg; for susp 125 mg/5ml, 250 mg/5mlCephalosporin entries
    cefixime cap 400 mg; for susp 100 mg/5ml, 200 mg/5mlCephalosporin entries
    1–10 of 33
    1/4
    Quantity limits — examples
    Azithromycin (tabs)QL 60 tablets/180 days
    Clarithromycin ERQL 28 tablets/180 days
    BAXDELA (delafloxacin)QL 28 tablets/180 days
    Tobramycin nebulized solution (Tobi)QL 280 mls/56 days
    TOBI PODHALER (tobramycin inhalation)QL 224 capsules/56 days
    Quantity limits — example set
    LYNPARZA (olaparib)QL 120 tablets/30 days
    COMETRIQ (cabozantinib kit)QL 1 kit/28 days
    BESREMI (ropeginterferon) prefilled syringesQL 2 syringes/28 days
    General oral tablet examplesQL 120 tablets/30 days; 60 tablets/30 days; 30 tablets/30 days
    Common example quantity limits
    Common tablet QLsExamples include 120 tablets/30 days and 30 tablets/30 days
    Typical time windowsQuantity limits commonly reported over 28-, 30- or 90-day windows as specified per product
    Pack/kit limitsSome products use kit/pack limits (e.g., starter packs with 1 pack/180 days)
    Selected quantity-limit examples (liquids/injectables)
    EOHILIA (budesonide oral suspension 2 mg/10 mL)QL 1800 mls/90 days
    Prednisolone sodium phosphate oral solution 15 mg/5 mLQL 900 mls/30 days
    Testosterone cypionate IM in oil 100 mg/mLQL 1 vial/28 days

    Provider Requirements, Prior Authorization & Step Therapy

    Prior Authorization

    Submit Prior Authorization when 'PA' is shown

    If a medication in the drug list shows 'PA' in the Requirements/Limits or Special Requirements column, the prescriber must submit a prior authorization request and obtain approval before the medication will be covered.

    • PA is noted next to products throughout the drug list; absence of an approved PA may result in denial or member responsibility for cost.
    Prior Authorization

    PA required for select specialty/antimycobacterial/antifungal agents

    Certain specialty antimycobacterial and antifungal agents (examples: ARIKAYCE, KITABIS PAK, tobramycin nebulized solutions, CRESEMBA, posaconazole, itraconazole) are listed with 'PA' (and often QL/SP); prescribers must request prior authorization for these products.

    • Tobramycin nebulized solution: Requirements/Limits = PA, QL (280 mls/56 days) and SP (or Bethkis QL 224 mls/56 days) [[chunk 31]]
    • CRESEMBA (isavuconazonium): Requirements/Limits = PA [[chunk 33]]
    • Itraconazole oral solution/capsules: QL/PA as listed (e.g., QL 1200 mls/30 days; QL 120 capsules/30 days) [[chunk 34]]
    Prior Authorization

    EPCLUSA: PA and QL (28 tablets/28 days)

    EPCLUSA (sofosbuvir-velpatasvir) requires prior authorization and is quantity-limited to 28 tablets (or 28 packs) per 28 days; it is designated for specialty pharmacy routing.

    • EPCLUSA lines show: Requirements/Limits = PA, QL (28 tablets/28 days) and SP [[chunk 39]].
    Prior Authorization

    HARVONI: PA and QL (28 tablets/28 days)

    HARVONI (ledipasvir-sofosbuvir) requires prior authorization, has a quantity limit of 28 tablets/28 days (or 28 packs/28 days), and is designated specialty pharmacy.

    • HARVONI lines show: Requirements/Limits = PA, QL (28 tablets/28 days) and SP [[chunk 40]].
    Prior Authorization

    DAA hepatitis C agents: PA, QL, SP

    Other direct-acting antivirals for hepatitis C (MAVYRET, VOSEVI, SOVALDI) are listed with prior authorization, specific quantity limits, and specialty pharmacy designation; submit PA and include supporting documentation.

    • MAVYRET, VOSEVI, and SOVALDI entries include Requirements/Limits = PA, QL and SP (per product lines in the formulary) [[chunk 47],[chunk 50]].
    Prior Authorization

    Obtain PA for listed oncology and specialty drugs

    Many antineoplastic and other listed oncology/specialty drugs are marked 'PA' (often with QL and SP); prescribers must obtain prior authorization before dispensing these agents.

    • Examples include abiraterone acetate (PA, QL 120 or 60 tablets/30 days) and ALECENSA (PA, QL 240 capsules/30 days) [[chunk 72],[chunk 73]].
    • PA is shown adjacent to numerous oncology product lines; lack of PA may trigger denial.
    Prior Authorization

    PA indicated in Requirements/Limits field — submit request

    Prior authorization is broadly required for many oncology agents and appears in the product Requirements/Limits field; submit PA requests for any product line showing 'PA'.

    • Product lines with 'Requirements/Limits = PA' require a PA submission prior to coverage.
    Prior Authorization

    PA and QL enforcement for specialty/oncology agents

    Many specialty and oncology products include both prior authorization and quantity limits; prescribers must obtain PA and request quantities within the QL shown on the formulary lines.

    • Examples: LYNPARZA (PA, QL 120 tablets/30 days), LYTGOBI (PA, QL 84/112/140 tablets/28 days) [[chunk 90],[chunk 99]].
    Prior Authorization

    Submit PA for listed non-oncology specialty products (e.g., EOHILIA)

    Selected non-oncology products also require prior authorization (examples include budesonide oral suspension EOHILIA and certain hormonal therapies); check product Requirements/Limits and submit PA when 'PA' is shown.

    • EOHILIA (budesonide oral suspension) is listed with Requirements/Limits = PA, QL (1800 mls/90 days) [[chunk 108]].
    • Some hormonal and specialty products (MYFEMBREE, ORIAHNN) show PA and QL on their lines.
    Prior Authorization

    PA required for listed endocrine/specialty agents (e.g., MOUNJARO, OZEMPIC)

    Several commonly used endocrinology and specialty products (e.g., certain metformin ER formulations, MOUNJARO, OZEMPIC, TRULICITY) are listed with 'PA' in Requirements/Limits; prescribers must submit PA requests for these products.

    • Metformin oral solution Riomet: Requirements/Limits = PA, QL (780 mls/30 days) [[chunk 133]].
    • MOUNJARO and OZEMPIC entries include PA and specified QL values [[chunk 134]].
    Prior Authorization

    PA required for endocrine and specialty agents (ACTHAR, GENOTROPIN, CRENESSITY)

    Multiple endocrine and specialty drugs (examples: ACTHAR, GENOTROPIN, CRENESSITY) are designated 'PA' (and many also 'SP'); the prescriber must obtain prior authorization and route dispensing through specialty pharmacy when required.

    • ACTHAR: Requirements/Limits = PA, SP; GENOTROPIN: Requirements/Limits = PA, SP; CRENESSITY: Requirements/Limits = PA, QL (60 capsules/30 days) [[chunk 151],[chunk 155]].
    Prior Authorization

    PA and Specialty Pharmacy required for select orphan/specialty agents

    Certain specialty/orphan agents (e.g., Kuvan, SKYTROFA, SOMAVERT, STRENSIQ, VOXZOGO) require prior authorization and often specialty pharmacy dispensing; submit PA and use specialty pharmacy routing as indicated.

    • Kuvan: PA, SP; SKYTROFA: PA, SP; SOMAVERT: PA, QL (30 vials/30 days), SP; VOXZOGO: PA, QL (30 vials/30 days), SP [[chunk 162],[chunk 163]].
    Step Therapy

    Follow Step Therapy requirements or request exception

    If step therapy (ST) is indicated (marked 'ST' on the drug list), the prescriber must document trial of the required first-line agent or submit a step therapy exception if the patient cannot use first-line therapy.

    • Step therapy exceptions must be requested by the prescriber or authorized representative by calling the number on the member ID card; decisions communicated within 3 business days (standard) or 24 hours for expedited requests [[chunk 15],[chunk 10]].
    Step Therapy

    Step therapy not fully specified in list — check 'ST' flags

    No comprehensive step therapy algorithms are provided in this excerpt; many products are managed by PA, QL, and SP flags rather than explicit ST sequences—check the formulary line for 'ST' where present.

    • Where 'ST' appears (e.g., KERENDIA), the prescriber must follow the step requirement or request an exception [[chunk 156],[chunk 36]].
    Prior Authorization

    REPATHA: PA and QL (6 syringes/28 days or 6 pens/28 days)

    REPATHA (evolocumab) products require prior authorization and have quantity limits of 6 syringes/28 days or 6 pens/28 days; obtain PA prior to dispensing and ensure QL compliance.

    • REPATHA prefilled syringe or auto-injector 140 mg: Requirements/Limits = PA, QL (6 syringes/28 days or 6 pens/28 days) [[chunk 198],[chunk 197]].
    Prior Authorization

    Obtain PA for listed specialty/high-cost cardiovascular & pulmonary drugs

    Many specialty/high-cost cardiovascular and pulmonary agents are listed with 'PA' (and often QL and SP); prescribers must obtain prior authorization before dispensing these products.

    • Examples: ENTRESTO (PA, QL 240 capsules/30 days), UPTRAVI (PA, QL 60 tablets/30 days), TYVASO starter kits (PA, QL) [[chunk 200],[chunk 204]].
    Prior Authorization

    PA required for specialty/biologic and CF agents (route via SP)

    Many specialty/biologic respiratory and cystic fibrosis therapies (examples: FASENRA PEN, NUCALA, TEZSPIRE, KALYDECO, TRIKAFTA) require prior authorization and are subject to quantity limits and specialty pharmacy routing; submit PA and route through specialty pharmacy.

    • FASENRA PEN: Requirements/Limits = PA, QL (1 pen/28 days), SP; NUCALA: Requirements/Limits = PA, QL (varies by presentation), SP; TRIKAFTA: Requirements/Limits = PA, QL (varies), SP [[chunk 217],[chunk 224]].
    Prior Authorization

    Prior authorization required for products labeled 'PA'

    Products explicitly labeled 'Requirements/Limits = PA' (examples shown: BYLVAY, GATTEX, LIVDELZI, LIVMARLI, CIMZIA, ENTYVIO PEN) require prior authorization prior to coverage approval; prescribers must submit PA requests.

    • CIMZIA entries show Requirements/Limits = PA and QL (2 kits/28 days or 4 syringes/28 days) [[chunk 239]].
    Prior Authorization

    PA required for selected products — submit before dispensing

    Selected products across the list require prior authorization before coverage will be approved; prescribers must submit PA requests for any product line indicating 'PA' in Requirements/Limits.

    • Examples: PROCYSBI, NUPLAZID and other product lines flagged 'PA' will require PA prior to coverage [[chunk 268]].
    Billing Rule

    Adhere to product-specific quantity limits when dispensing

    For products with specified QL (e.g., EPCLUSA 28 tablets/28 days, HARVONI 28 tablets/28 days, REPATHA 6 syringes/28 days), ensure the dispensed quantity adheres to the QL to avoid denial or member cost responsibility.

    • EPCLUSA: QL 28 tablets/28 days; HARVONI: QL 28 tablets/28 days; REPATHA: QL 6 syringes/28 days or 6 pens/28 days [[chunk 39],[chunk 40],[chunk 197]].
    Denial Risk

    Avoid exceeding formulary quantity limits (QL)

    Prescriptions that exceed plan dispensing or quantity limits (QL) may be denied or result in the member being responsible for the full cost of the medication; ensure prescribed quantities do not exceed the listed QL.

    • For certain controlled substances, state law may prohibit coverage of quantities beyond dispensing limits; member could be responsible for full cost [[chunk 10],[chunk 109]].
    • Claims exceeding QL may be denied per plan rules [[chunk 20]].
    Note
    Note
    Note
    Note

    Initial Therapy and Authorization Rules

    Initial therapy controls

    Initial coverage controls shown per product

    Initial per-product controls: Certain products require prior authorization and are subject to quantity limits on initial prescribing (examples shown for metformin oral solution Riomet PA+QL; MOUNJARO and OZEMPIC listed with PA and QL).

    No specific clinical initiation criteria are provided in these chunks

    Initial administrative requirements

    Initial authorization requirements (as provided in this excerpt)

    Initial administrative requirements: For initial dispensing, request prior authorization where 'PA' is listed and route orders through specialty pharmacy where 'SP' is listed; respect any listed quantity limits (QL).

    Clinical medical necessity criteria for initiation are not included in this fragment

    Initial therapy rules (not specified)

    No explicit initial therapy criteria are provided in this excerpt.

    Initial coverage: Coverage and dispensing are according to formulary tier; where PA is listed, approval is required prior to initial dispensing.

    Specific clinical initiation rules not included here

    Step Therapy Rules and Affected Agents

    Step therapy principle
    Try preferred first-line, cost-effective medication unless an exception is granted (prescriber may request a step therapy exception).
    Note
    No explicit step therapy steps are provided in the formulary listing; utilization management is applied per product using prior authorization (PA), quantity limits (QL), and specialty pharmacy (SP) designations as shown on the drug list.
    ART product management
    Several combination antiretroviral (ART) products are subject to quantity limits (commonly QL (30 tablets/30 days) for listed agents such as BIKTARVY, CIMDUO, DELSTRIGO and others); explicit step edits are not specified in these entries.
    Oncology/specialty step therapy note
    Multiple oncology and specialty agents are listed with specialty (SP) and prior authorization (PA) requirements and quantity limits (QL); some products are indicated as subject to step therapy (ST) — specific step sequences are not provided in these chunks.
    KERENDIA (finerenone)
    KERENDIA (finerenone) 10 mg, 20 mg is listed with a quantity limit of QL (30 tablets/30 days) and is marked 'ST' indicating step therapy requirements apply; specific step criteria are not included in these excerpts.
    AUVELITY
    AUVELITY (dextromethorphan HBr–bupropion HCl) is listed with 'ST' in Requirements/Limits, indicating it is subject to step therapy requirements as noted on the drug list.
    DESVENLAFAXINE ER
    DESVENLAFAXINE ER is identified with 'ST' in the Requirements/Limits field in the formulary excerpts, indicating it is subject to step therapy requirements.
    ESCITALOPRAM OXALATE
    ESCITALOPRAM OXALATE (e.g., 15 mg cap) is listed with 'ST' in the Requirements/Limits field, indicating step therapy applies per the drug list notation.
    FETZIMA
    FETZIMA (levomilnacipran) extended‑release capsules are marked 'ST' in the Requirements/Limits column, indicating they are subject to step therapy requirements per the formulary listing.
    QUETIAPINE FUMARATE (some strengths)
    Certain quetiapine fumarate tablet presentations (examples in the listing) include 'QL' and are specifically noted with 'ST' for some strengths — indicating selected strengths are subject to step therapy as shown in the drug list.
    RISPERIDONE ODT (certain strengths)
    Risperidone orally disintegrating tablets (ODT) at certain strengths are listed with QL and are marked 'ST' for selected presentations, indicating step therapy requirements apply to those strengths as shown in the formulary excerpt.

    Quantity Limits and Examples

    Per-product QL examples — selected anti-infectives
    Azithromycin tabs (250 mg, 500 mg)QL 60 tablets/180 days
    Omadacycline (Nuzyra) 150 mg tabQL 30 tablets/180 days
    BAXDELA (delafloxacin) 450 mg tabQL 28 tablets/180 days
    Tobramycin nebulized solutions (Tobi/Bethkis)QL 280 mls/56 days and QL 224 mls/56 days respectively
    TOBI PODHALER (tobramycin inhal cap 28 mg)QL 224 capsules/56 days
    Omadacycline (Nuzyra) QL
    Omadacycline (Nuzyra) 150 mg tabQL 30 tablets/180 days
    Sarecycline (Seysara)Listed with QL/requirements as shown
    Tetracycline class examplesVarious tetracycline entries with specified QLs where noted
    BAXDELA (delafloxacin) quantity limit
    BAXDELA - delafloxacin 450 mgQL 28 tablets/180 days
    Fluoroquinolone listingsOther fluoroquinolones shown with per-product QLs as specified
    Document sourceFormulary line lists QL adjacent to product name
    Tobramycin nebulized solutions — QLs
    Tobramycin nebulized solution (Tobi) 300 mg/5 mLQL 280 mls/56 days
    Tobramycin nebulized solution (Bethkis) 300 mg/4 mLQL 224 mls/56 days
    PA and SP designationsThese inhaled aminoglycoside products are listed with PA and SP where shown
    TOBI PODHALER quantity limit
    TOBI PODHALER (tobramycin inhalation) 28 mg capsQL 224 capsules/56 days
    SP designationListed as SP where indicated in the formulary
    Refer to product line for PAPA noted in adjacent Requirements/Limits when required
    Itraconazole / Posaconazole QLs
    Itraconazole oral solution (10 mg/mL)QL 1200 mls/30 days
    Itraconazole capsulesQL 120 capsules/30 days
    Posaconazole formulationsPA and QL specified for delayed-release and suspension presentations
    Antiviral / ART quantity limits
    Antiviral combination products (e.g., BIKTARVY)Typically QL 30 tablets/30 days
    CIMDUO and similar ART combosListed with QL 30 tablets/30 days in formulary entries
    Per-product variationSome antivirals have alternate QLs noted per strength/pack
    BIKTARVY quantity limit
    BIKTARVY (bictegravir-emtricitabine-tenofovir)QL 30 tablets/30 days
    TieringListed with Drug Tier = P in formulary
    Refer to line item for pack variationsSome presentations (e.g., tablets vs packets) may differ
    EPCLUSA QL and PA
    EPCLUSA (sofosbuvir-velpatasvir)QL 28 tablets/28 days; Requirements/Limits = PA, SP
    Pellet pack presentationsEPCLUSA pellet packs listed with QL 28 packs/28 days
    PA requirementPA required as noted in the product line
    HARVONI QL and PA
    HARVONI (ledipasvir-sofosbuvir)QL 28 tablets/28 days; Requirements/Limits = PA, SP
    Pellet pack presentationsHARVONI pellet packs listed with QL 28 packs/28 days
    PA and specialty pharmacyPA and SP designations present in formulary entry
    PAXLOVID quantity limits
    PAXLOVID (nirmatrelvir + ritonavir pack)QL 11 tablets/90 days (example pack listing); other pack QLs shown
    Multiple pack sizesFormulary lists alternate pack QLs (e.g., 11, 20, 30 tablets/90 days) depending on pack
    PA not routinely requiredPA not shown for standard PAXLOVID pack in these chunks
    SUNLENCA quantity limit
    SUNLENCA (lenacapavir) therapy packQL 4 tablets/365 days (or 5 tablets/365 days depending on pack)
    Long-acting HIV agentsTherapy packs have annual QLs as indicated
    Refer to formulary lineExact QL depends on listed pack presentation
    Clindamycin kit QL
    Clindamycin topical/oral kitsQL 1 kit/56 days
    Cleocin formulationsCapsules and pediatric solutions listed with standard tiers
    Kit-based dispensingKits limited per 56-day window as shown
    Linezolid / vancomycin quantity limits
    Linezolid oral suspension (Zyvox) 100 mg/5 mLQL 600 mls/180 days
    Linezolid tablets 600 mgQL 56 tablets/180 days
    Vancomycin capsules (Vancocin)QL 120 capsules/30 days
    Linezolid and related oxazolidinone QLs
    Linezolid 600 mg tabletsQL 56 tablets/180 days
    Linezolid suspensionQL 600 mls/180 days
    SIVEXTRO (tedizolid) 200 mgQL 6 tablets/180 days
    Vancomycin / Rifaximin QLs
    Vancomycin capsules (Vancocin)QL 120 capsules/30 days
    XIFAXAN (rifaximin) 200 mgQL 9 tablets/30 days
    XIFAXAN 550 mgQL 126 tablets/365 days
    SIVEXTRO quantity limit
    SIVEXTRO (tedizolid) 200 mgQL 6 tablets/180 days
    Tedizolid listingFormulary line indicates QL adjacent to product
    Related QL enforcementExceeding QL may lead to denial per policy guidance
    XIFAXAN quantity limits
    XIFAXAN 200 mgQL 9 tablets/30 days
    XIFAXAN 550 mgQL 126 tablets/365 days
    Indication-specific QLsDifferent dosing strengths have distinct QL windows (30 days vs 365 days)
    Abiraterone acetate QLs
    Abiraterone acetate 250 mgQL 120 tablets/30 days
    Abiraterone acetate 500 mgQL 60 tablets/30 days
    PA and SP notedBoth strengths listed with PA and SP in formulary entries
    AUGTYRO quantity limits
    AUGTYRO (repotrectinib) 40 mgQL 240 capsules/30 days
    AUGTYRO 160 mgQL 60 capsules/30 days
    Per-strength QLsFormulary shows capsule-count limits per 30-day period
    ALECENSA quantity limit
    ALECENSA (alectinib) 150 mg capsQL 240 capsules/30 days
    PA and SP designationsListed with PA and SP in formulary
    Refer to product line for pack detailsPer-strength packaging may affect QL enforcement
    Abiraterone 250 mg — QL
    Abiraterone acetate 250 mg120 (tablets/30 days)
    ContextListed with PA and SP in product Requirements/Limits
    Alternate strengthSee separate line for 500 mg QL 60 tablets/30 days
    Abiraterone 500 mg — QL
    Abiraterone acetate 500 mg60 (tablets/30 days)
    PA/SPPA and SP noted on formulary line
    Clinical notePer-product QL applies as listed
    ALECENSA 150 mg — QL
    ALECENSA alectinib 150 mg240 (capsules/30 days)
    Formulary annotationPA and SP indicated in product line
    Dispensing noteAdhere to QL when submitting claims or PA requests
    AYVAKIT quantity limit
    AYVAKIT (avapritinib)QL 30 tablets/30 days
    PA/SPPA and SP present in formulary entry
    Per-strength listingAll specified strengths subject to same monthly QL unless otherwise noted
    COMETRIQ kit — QL
    COMETRIQ (cabozantinib) kitQL 1 kit/28 days
    Kit-based QLRepeated across kit presentations in formulary entries
    PA and SPPA and SP noted where applicable
    GOMEKLI quantity limits
    GOMEKLI (mirdametinib)QL 168 (capsules/tablets/28 days) depending on presentation
    PA and SPPA and SP indicated for product lines
    Per-presentation varianceDifferent capsule strengths have alternate QLs noted
    LYNPARZA quantity limit
    LYNPARZA (olaparib) 100/150 mgQL 120 tablets/30 days
    PA and SPRequirements/Limits indicate PA and SP for coverage
    Apply per 30-day windowQL shown applies over 30-day period unless otherwise specified
    ROZLYTREK quantity limits
    ROZLYTREK (entrectinib) cap 100 mgQL 336 packets/28 days (packet presentation) — see alternate line for 30 capsules/30 days
    Multiple presentation QLsFormulary lists packet- and capsule-based QLs per pack type
    PA/SPPA and SP indicated in product line
    VITRAKVI quantity limits
    VITRAKVI oral solutionQL 300 mls/30 days
    VITRAKVI capsulesQL 180 capsules/30 days or 60 capsules/30 days depending on strength
    PA and SPPA and SP noted for VITRAKVI entries
    VENCLEXTA starter pack QL
    VENCLEXTA starter packQL 1 pack/180 days
    VENCLEXTA tabletsPer-strength QLs shown (e.g., 60 tablets/30 days) in formulary lines
    PA and SPPA and SP indicated in product Requirements/Limits
    EOHILIA quantity limit
    EOHILIA (budesonide oral suspension 2 mg/10 mL)QL 1800 mls/90 days
    Formulary annotationListed with PA in product Requirements/Limits
    Provider actionPA required where indicated for coverage
    Prednisolone solution — QL
    Prednisolone sodium phosphate oral solution 15 mg/5 mLQL 900 mls/30 days
    Other prednisolone solutionsAlternate QLs listed (e.g., 450 mls/30 days) for different strengths
    QL enforcement noteExceeding listed QL may lead to claim denial per policy guidance
    Testosterone injection QL
    Testosterone cypionate IM injection in oil 100 mg/mLQL 1 vial/28 days
    Other testosterone presentationsVarious IM and transdermal presentations carry PA and QL as listed
    Provider actionSubmit PA where 'PA' is indicated in product line
    Mixed quantity-limit examples (tablets, patches, pens, mL)
    Short window examples28 tablets/21 days; 3 patches/21 days
    Common monthly examples30 tablets/30 days; 60 tablets/30 days
    Pen/auto-injector examples1 pen/28 days; 4 pens/28 or 180 days
    Liquid insulin examples100 mls/30 days commonly applied to many insulin products
    Insulin common quantity limit
    Multiple insulin products (example)QL 100 mls/30 days — common across rapid/short/intermediate/basal/mix insulins
    Products listedNOVOLIN 70/30, NOVOLOG MIX 70/30, insulin glargine products, TRESIBA — each with QL 100 mls/30 days
    Apply per 30-day windowQL enforced monthly unless otherwise specified
    CRENESSITY quantity limits
    CRENESSITY (capsules)QL 60 capsules/30 days
    CRENESSITY (oral solution)QL 120 mls/30 days
    PA and SPProduct lines show PA and SP where applicable
    CRENESSITY (oral solution) QL
    CRENESSITY oral solutionQL 120 mls/30 days
    Capsule counterpartSee capsule QL (60 capsules/30 days)
    DocumentationPA and QL noted in product Requirements/Limits — provide supporting documentation when requesting PA
    Specialty/orphan drug QL examples
    High-cost specialty examplesIMCIVREE QL 10 vials/30 days; GALAFOLD QL 14 capsules/28 days; JYNARQUE QLs vary
    Vials/capsules/device limitsMany orphan/specialty agents use vials, pens or device-based QLs (e.g., 30 vials/30 days)
    PA and SPPA and SP designations accompany many of these entries
    SOMAVERT quantity limit
    SOMAVERT (pegvisomant) vialsQL 30 vials/30 days
    PA and SPListed with PA and SP in formulary entry
    Provider noteRequests should include supporting documentation per PA guidance
    VOXZOGO quantity limit
    VOXZOGO (vosoritide)QL 30 vials/30 days
    PA and SPPA and specialty pharmacy designation noted
    QL enforcementQuantity limits must be respected when submitting PA or claims
    TRYNGOLZA quantity limit
    TRYNGOLZA (olezarsen) injection deviceQL 1 injection device/28 days
    PA and SPFormulary lists PA and SP where applicable
    Device-based QLsSome therapies limited by device count rather than unit count
    TYMLOS quantity limit
    TYMLOS (abaloparatide) pen-injector 3.12 mg/1.56 mLQL 1.56 mls/30 days
    PA and SPListed with PA and SP as applicable
    Per-month QLVolume-based QL applied monthly
    YORVIPATH quantity limit
    YORVIPATH (palopegteriparatide) pensQL 2 pens/28 days
    PA and SPPA and specialty pharmacy noted in product entry
    Device-count QLPen-count limits commonly used for these agents
    SOTYLIZE and selected oral product QLs
    SOTYLIZE (sotalol oral solution)QL 1920 mls/30 days (example)
    Selected oral product QLsExamples include 120 tablets/30 days for some oral therapies
    PA where notedPA applies to some liquid formulations as listed
    Epaned quantity limit
    Enalapril maleate oral solution (Epaned) 1 mg/mLQL 1200 mls/30 days
    PA indicatedThis oral solution line shows PA alongside the QL
    Provider noteProvide documentation to support PA and requested quantity
    TRYVIO quantity limit
    TRYVIO (aprocitentan 12.5 mg)QL 30 tablets/30 days
    PA and SPPA and SP indicated in product Requirements/Limits
    Special handlingProduct has special handling/service designation in formulary
    REPATHA quantity limit
    REPATHA prefilled syringe/auto-injector 140 mgQL 6 syringes or 6 pens/28 days
    PA requiredFormulary lists PA alongside the QL for REPATHA
    Specialty dispensingSP designation applies to specialty biologic products
    FUROSCIX quantity limit
    FUROSCIX (furosemide subcutaneous cartridge kit) 80 mg/10 mLQL 8 kits/180 days
    PA indicatedPA listed in product Requirements/Limits
    Long-term QL windowSome device/kit QLs span 180 days
    INZIRQO quantity limit
    INZIRQO (HCTZ suspension 10 mg/mL)QL 160 mls/30 days
    PA indicatedPA present for certain oral suspensions as listed
    Refer to line itemExact QL shown adjacent to product name in formulary
    NEXLETOL / NEXLIZET quantity limits
    NEXLETOL / NEXLIZETQL 30 tablets/30 days
    PA indicatedPA listed with QL in product Requirements/Limits
    Per-month QLStandard monthly QL applied unless otherwise noted
    Droxidopa quantity limits
    Droxidopa (Northera) 100 mgQL 450 capsules/30 days
    Droxidopa 200/300 mgQL 180 capsules/30 days
    PA indicatedPA listed alongside QL for Northera formulations
    QBRELIS quantity limit
    QBRELIS (lisinopril oral solution 1 mg/mL)QL 2400 mls/30 days
    PA indicatedPA appears in Requirements/Limits for some oral solutions
    Large-volume QLsCertain oral solutions have high mL-per-month limits listed
    Selected cardiovascular / specialty QLs
    REPATHAQL 6 syringes/28 days or 6 pens/28 days
    ATTRUBYQL 112 tablets/28 days
    ORENITRAMQL 300 tablets/30 days
    Pulmonary / PAH product QLs
    UPTRAVI (selexipag)QL 60 tablets/30 days
    Pulmicort (budesonide inhalation susp) 0.25/0.5 mg/2 mLQL 120 mls/30 days
    Pulmicort 1 mg/2 mL presentationsQL 240 mls/30 days
    Biologic respiratory agent QLs
    FASENRA PEN (benralizumab)QL 1 pen/28 days
    NUCALA (mepolizumab)QL varies by presentation (e.g., 3 pens/28 days; 1 syringe/28 days)
    TEZSPIRE (tezepelumab)QL 1 pen/28 days
    Cystic fibrosis and related specialty QLs
    ALYFTREK (CF triple therapy)QL 84 tablets/28 days or 56 tablets/28 days depending on formulation
    TRIKAFTA (CF modulators)QL 56 packets/28 days (example) — other packet/ tablet QLs listed
    ZYMFENTRA (infliximab-dyyb)QL 2 pens/28 days or 2 syringes/28 days
    Aprepitant / Emend quantity limits
    Emend (aprepitant) tripackQL 3 packs/30 days
    Aprepitant 40 mg capsuleQL 2 capsules/30 days
    Emend oral suspension 125 mg kitQL 9 kits/30 days
    Selected GI / immunology QLs
    AURYXIA / Ferric citrateQL 1080 tablets/365 days
    CIMZIA prefilled syringe kitQL 2 kits/28 days (alternate line shows 4 syringes/28 days)
    Lanthanum carbonate powder pack 750 mgQL 540 packs/365 days
    Selected biologic QLs
    SKYRIZI (risankizumab)QL 1 cartridge/56 days
    TREMFYA induction packQL 3 kits/180 days
    VOWSTQL 12 capsules/12 months
    BUCAPSOL (buspirone) quantity limits
    BUCAPSOL (buspirone) 7.5 mg capQL 60 capsules/30 days
    BUCAPSOL 10 mg capQL 90 capsules/30 days
    BUCAPSOL 15 mg capQL 120 capsules/30 days
    Antipsychotics — quantity-limit examples
    Antipsychotic examplesQLs vary (30, 60, 90, 120 tablets/30 days or specified mL limits) per product/strength
    Quetiapine examplesQL 30–180 tablets/30 days depending on formulation/strength
    Risperidone / clozapine QLsRisperidone QLs 60–480 mls/30 days; Clozapine QL examples 90 tablets/30 days
    NUPLAZID quantity limit
    NUPLAZID (pimavanserin) 34 mgQL 30 capsules/30 days
    PA indicatedPA listed alongside QL in formulary entry
    Monthly QLStandard 30-day QL window applied

    Site of Care and Specialty Pharmacy

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Terminology and Abbreviations

    Definition — Specialty drugs
    Specialty drugs — definitionMedications used to treat complex conditions; may be oral, topical or injectable and may require special handling or support
    Administration siteMedications administered by a health care professional may be covered under the medical benefit rather than the pharmacy benefit
    Where to find current listFor a current list of specialty medications, visit MyPrime.com or bcbsnm.com
    Definition — Generic equivalent vs alternative
    Generic equivalent vs generic alternativeGeneric equivalent: same active ingredient and dosage as reference brand; Generic alternative: treats same condition but different active ingredient(s)
    FDA standardsFDA-approved generics meet same standards for safety, efficacy, and quality as brand counterparts
    Member cost-share noteMember may pay difference if choosing reference brand over generic equivalent
    Definition — Drug tier codes (P / NP)
    P / NP tier codes'P' = Preferred; 'NP' = Non-Preferred (tier shown on drug line)
    Case variationsDocument uses varying case (p, np, P, NP) to indicate plan-specific tiering
    Refer to benefit planGroup-specific coverage indicated by '+' may affect member cost-share
    Definitions — Utilization designators (PA / QL / SP)
    PA / QL / SP definitionsPA = Prior Authorization; QL = Quantity Limit; SP = Specialty Pharmacy designation
    QL formatLimits shown as counts/volume per time window (e.g., '28 tablets/180 days', '280 mls/56 days')
    Provider actionWhen 'PA' is listed, prescriber must submit a prior authorization request before coverage

    Background and Scope

    Specialty drugs are high‑complexity or high‑cost medications used to treat conditions such as hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis. They may require special handling, patient support, or administration by a health care professional. When a specialty product is administered in a clinical setting it may be billed through the medical benefit; when dispensed for self‑administration it is typically managed through the pharmacy benefit and, when designated, must be routed through a specialty pharmacy partner.